Clinical trials · Washington, D.C., DC
Cancer clinical trials in Washington, D.C.
We’re tracking 968 recruiting cancer studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05208047RecruitingPhase 3
CGT9486 plus sunitinib for advanced gastrointestinal stromal tumors
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06513962RecruitingPhase 3
Triptorelin to protect ovaries in young women with cancer
This study tests whether a medicine called triptorelin can protect the ovaries in young women and teens receiving strong chemotherapy for cancer. If you are newly diagnosed with a cancer (other than breast cancer) and are about to get certain chemotherapy drugs, this trial may help preserve your fertility.
Washington D.C., District of ColumbiaAges Up to 39 years - NCT04865887RecruitingPhase 2
Pembrolizumab plus lenvatinib for advanced cervical cancer
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05999994RecruitingPhase 2
Testing new drugs for children and young adults with cancer
This trial tests several experimental drugs for children and young adults with cancer. It aims to find safe and effective treatments by matching participants to one of several drug studies based on their cancer type and health.
Washington D.C., District of ColumbiaAges 1–39 - NCT06136650RecruitingPhase 3
Study of a new drug for advanced prostate cancer
This study tests a new oral drug called opevesostat against another standard hormone therapy for men with advanced prostate cancer that has spread and is no longer controlled by a first hormone therapy. It's for men who have not had chemotherapy for this stage and who have not used a PARP inhibitor or chose not to.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06701812RecruitingPhase 2
Digoxin for relapsed non-WNT non-SHH medulloblastoma
This trial tests whether the drug digoxin can help treat medulloblastoma that has come back after standard treatments like chemotherapy and radiation. Digoxin is a heart medicine being studied for its anticancer effects against a specific type of medulloblastoma.
Washington D.C., District of ColumbiaAges 1–30 - NCT06172296RecruitingPhase 3
Dinutuximab plus transplant for high-risk neuroblastoma
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Washington D.C., District of ColumbiaAges Up to 30 years - NCT05668962RecruitingPhase 2
Study selpercatinib plus I-131 for RET thyroid cancer that cannot take iodine
This trial tests whether combining a targeted pill (selpercatinib) with a radioactive iodine dose (I-131) can shrink thyroid cancer that has spread and no longer responds to radioactive iodine. It is for RET fusion–positive (genetically driven) thyroid cancers where the cancer cannot reliably absorb iodine anymore.
Washington D.C., District of ColumbiaAges 12 years+ - NCT05987241RecruitingPhase 2/Phase 3
Using a blood test to guide immunotherapy after bladder/kidney cancer surgery
This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07284849RecruitingPhase 3
Testing a new drug combo for advanced colorectal cancer
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07007559RecruitingPhase 2
Evorpacept with trastuzumab and chemo for HER2-positive breast cancer
This study tests an experimental drug called evorpacept when given with trastuzumab and chemotherapy for people with HER2-positive breast cancer that has spread. The goal is to see if this combination can shrink tumors or slow down the cancer.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07154290RecruitingPhase 2
Ubamatamab with or without REGN7075 for advanced lung cancer
This trial tests a new targeted therapy (ubamatamab) alone or with another drug (REGN7075) for people with advanced or metastatic non-small cell lung cancer that has gotten worse after standard treatment. It aims to see if targeting MUC16, a substance found on some cancer cells, can help control the cancer.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06806930RecruitingPhase 2
Predicting response to hormone therapy before breast cancer surgery
This trial tests whether we can predict how well hormone therapy works before surgery for early-stage breast cancer. It may help women with estrogen receptor-positive, HER2-negative or HER2-low breast cancer avoid or tailor treatments.
Washington D.C., District of ColumbiaAges 21 years+ - NCT07318519Recruiting
Virtual reality for chronic cancer pain
This study tests whether virtual reality (VR) can help reduce chronic pain in people with cancer. If you have had cancer pain for at least three months and rate your pain as 4 or more out of 10, you may be able to join.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Washington D.C., District of ColumbiaAges 40–75 - NCT05335928RecruitingPhase 3
Abatacept for immune-therapy heart inflammation in hospitalized adults
This Phase 3 trial tests abatacept to treat myocarditis (inflammation of the heart muscle) caused by immune checkpoint cancer medicines. It may help patients recover faster and safely manage this serious side effect while they are in the hospital.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06596694RecruitingPhase 1/Phase 2
Patritumab deruxtecan for advanced gastrointestinal cancers
This trial tests a new drug (patritumab deruxtecan) for people with advanced or spreading cancers of the digestive system (including colorectal, bile duct, liver, and stomach/esophageal cancers). The goal is to see if it can shrink tumors or stop them from growing.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06661720RecruitingPhase 3
Tivozanib and pembrolizumab after kidney cancer surgery
This trial is testing if adding the targeted therapy tivozanib to the immunotherapy drug pembrolizumab (Keytruda) can help prevent kidney cancer from coming back after all known tumors have been removed by surgery.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04752722RecruitingPhase 1/Phase 2
Gene therapy for bladder cancer that came back after BCG
This study tests a new gene therapy (EG-70) given directly into the bladder for people with a high-risk bladder cancer called NMIBC. It may be an option if BCG treatment stopped working, or if you cannot have or choose not to have bladder removal surgery.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06748222RecruitingPhase 3
Online mindfulness program for breast cancer survivors
This trial tests a 6-week online mindfulness program to help breast cancer survivors manage mild to moderate depression. You may qualify if you finished active treatment within the last 5 years and can use a digital device.
Washington D.C., District of ColumbiaAges 18–50 - NCT04251052Recruiting
Compare two surgeries to lower ovarian cancer risk in BRCA1 carriers
This study compares two risk-reducing surgery plans for people with a BRCA1 genetic change to see which approach helps lower ovarian cancer risk. You may be asked to have the study procedure sooner or later depending on your chosen plan.
Washington D.C., District of ColumbiaAges 35–50
Hear when a new Cancer trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting cancer studies listed above.
- George Washington University Hospital · 8 studies
- MedStar Washington Hospital Center · 8 studies
- University of Maryland Greenebaum Comprehensive Cancer Center · 6 studies
- MedStar Georgetown University Hospital · 5 studies
- Walter Reed National Military Medical Center · 5 studies
- Children's National Medical Center · 4 studies
- Inova Schar Cancer Institute · 4 studies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 4 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in District of Columbia.
Common questions
- Are there cancer clinical trials near Washington, D.C.?
- Yes. We're currently tracking 968 recruiting cancer studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.